How Biotech And Pharma Adopt AI And The Supply Chain Opportunities

Biotech and pharma are rapidly adopting AI. NVIDIA’s State of AI in Healthcare and Life Sciences report found that 74% of pharma and biotech organizations are actively using AI. About half (47%) report ROI from AI for drug discovery and development, and 48% are using AI agents for drug discovery and biomarker identification.

The Benchling 2026 Biotech AI Report also reports AI adoption. The report found that 46% of biotech and pharma organizations are using AI apps and scientific models in R&D regularly, and a majority of them (81%) use it for scientific use cases.

AI Biotech: AI-Powered Drug Discovery and Development

Benchling’s report says that about half of those adopting AI report faster time-to-target, 56% expect meaningful cost reductions within two years, and 42% see an uplift in accuracy and hit rates.

“90% of clinical trial failures happen in Phase 2 or 3 clinical trials, not in discovery,” Iker Huerga, CEO at Pathos, says.

“That is where AI has to work if it is going to change medicine, and it is where almost no one is actually building.”

Pathos is an AI and technology company that develops drugs. Its core is Pathos Foundry, a home-grown platform running thousands of AI agents that reason continuously over more than 200 petabytes of multimodal patient data, Pathos’ real-time clinical trial systems, Pathos’ wet-lab experiments, and published literature.

“It does three things a traditional biotech does not,” says Huerga. “It sources drug candidates from data other companies never look at, designs and steers clinical trials in real time, and makes disciplined stop decisions early, before hundreds of millions of dollars are burned on assets that were never going to work,” says Huerga.

In the last 12 months, Foundry has made four platform-informed decisions across four different drugs, each one changed the trajectory of the program. “That is what happens when AI stops being a slide in a deck and starts making the decisions that matter,” says Huerga.